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PREFACE
A memorandum of understanding has been signed by two government agencies in the United States 
and Sweden—the Division of Standards Development and Technology Transfer of the National 
Institute for Occupational Safety and Health, U.S. Department of Health and Human Services 
(DSDTT/NIOSH), and the Criteria Group of Occupational Standard Setting, Research Department, 
National Institute of Occupational Health (NIOH) (formerly National Board of Occupational Safety 
and Health). The purpose of the memorandum is to exchange information and expertise in the area 
of occupational safety and health. One product of this agreement is the development of documents 
to provide the scientific basis for establishing recommended occupational exposure limits. These 
limits will be developed separately by the two countries according to their different national policies.
This document on the health effects of occupational exposure to acrylamide is the fourth product 
of that agreement. The document was written by Vlasta Molak, Ph.D., D.A.B.T. (DSDTT/NIOSH), 
and was reviewed by the Criteria Group and by DSDTT/NIOSH.
Richard W. Niemeier, Ph.D.
Director/DSDTT
NIOSH
Bo Holmberg 
Chairman/Criteria Group 
NIOH
CONTENTS
Preface..................................................................................................................................................... iii
Acknowledgments............................................................................................................................. vii
1 BACKGROUND..........................................................................................................................  1
1.1 Chemical and Physical Properties...................................................................................  1
1.2 Production and Use of Acrylamide.................................................................................  1
1.3 Potential for Occupational Exposure............................................................................... 1
1.4 Existing Standards and Recommendations...................................................................... 4
2 TOXICOLOGY............................................................................................................................. 5
2.1 Metabolism..........................................................................................................................  5
2.1.1 Uptake.......................................................................................................  5
2.1.2 Distribution and toxicokinetics..............................................................................  5
2.1.3 Biotransformation and elimination........................................................................ 6
2.1.4 Factors that can affect metabolism........................................................................  7
2.2 Toxicologic Mechanisms...................................................................................................  8
2.3 Toxicity in Humans and Animals...................................................................................  8
2.3.1 Neurotoxic effects.....................................................  9
2.3.2 Developmental and reproductive effects............................................................... 10
2.4 Genotoxic Effects............................................................................................................... 15
2.4.1 Gene mutation assays..............................................................................................  15
2.4.2 Chromosomal assays................................................................................................. 15
2.5 Carcinogenic Effects..........................................................................................................  16
2.5.1 Epidemiologic findings............................................................................................  16
2.5.2 Evidence of carcinogenicity in animals.................................................................  17
v
Contents
3 METHODS FOR MONITORING EXPOSURES  ........................................ 20
3.1 Exposure Monitoring........................................................................................................... 20
3.2 Biological Monitoring............................................................................................................. 20
4 RELATIONSHIP BETWEEN EXPOSURE AND ADVERSE HEALTH EFFECTS . 21
5 RESEARCH NEEDS...................................................................................................25
6 DISCUSSION AND EVALUATION.........................................................................  27
7 SUMMARY...............................................................................................................  28
8 REFERENCES............................................................................................................29
9 APPENDIX...............................................................................................................  37
ACKNOWLEDGMENTS
The following staff members of the Division of Standards Development and Technology Transfer, 
National Institute for Occupational Safety and Health, were responsible for preparing this 
document.
C riter ia  M an ager
Vlasta Molak, Ph.D., D.A.B.T.
C hief, S en io r  R eview  A ctivity
John Whalen
S en ior  R eview  S ta ff
Jerome P. Flesch 
G. Kent Hatfield, Ph.D. 
Robert W. Mason, Ph.D. 
Leslie T. Stayner
E d itor ia l S ta ff
Vanessa L. Becks 
Ruth E. Grubbs 
Anne C. Hamilton
C hief, D ocu m en t D evelop m en t G roup II
Howard R. Ludwig
C hief, D ocu m en t D evelop m en t B ranch
Ralph D. Zumwalde
A cting  A sso c ia te  D irector  for  
P olicy  D evelop m en t
Laurence D. Reed
D eputy D irector, D SD T T
Bryan D. Hardin, Ph.D.
D irector, D SD T T
Richard W. Niemeier, Ph.D.
S ecretaria l S ta ff
Sharon L. Cheesman
Contributions by other NIOSH staff members are also gratefully acknowledged:
R eview ers
Paul E. Caplan 
Peter M. Eller, Ph.D.
Nicholas Hahon 
Bruce W. Hills 
William J. Moorman 
B. K. Nelson, Ph.D.
Walter E. Ruch, Ph.D.
1 BACKGROUND
1.1 CHEMICAL AND PHYSICAL PROPERTIES
Acrylamide is an odorless, white, crystalline solid used as a monomer or as a raw material in the 
production of polyacrylamides and other compounds. Chemical and physical properties of 
acrylamide are given in Table 1. Because most of the aciylamide monomer is produced and used 
as an aqueous solution, the physical properties of a 50% aqueous solution of acrylamide are also 
given (Table 2).
1.2 PRODUCTION AND USE OF ACRYLAMIDE
In 1985,140 million lb (63,600 metric tons) of acrylamide were produced in the United States, and 
predictions in 1988 indicated that 164 million lb (74,500 metric tons) of this chemical would be 
produced in 1989 [EPA 1988a]. Total acrylamide production capacity in western Europe was
93.5 million lb (42,500 metric tons) in 1984, and the estimated production in Japan was 90 million lb 
(41,000 metric tons) in 1982 [WHO 1985]. Acrylamide is also used and produced in the Soviet 
Union and China, but production estimates have not been reported [He et al. 1989].
The reactive acrylamide monomer is used in the production of other compounds (mostly polymers 
of acrylamide) and as a grouting agent in the construction or rehabilitation of dams, buildings, 
sewers, tunnels, and other structures.
Acrylamide grouts are used predominantly as barriers against groundwater seepage into sewers. 
About 95% of the acrylamide produced in the United States is consumed in the production of other 
compounds and polyacrylamide products that are widely used as (1) flocculents in potable water and 
wastewater treatment, mineral ore processing, and sugar refining, (2) water flow control agents in 
oil well operations, and (3) adhesives in papermaking and construction [Davidson et al. 1980]. The 
remaining 5% is used as a monomer [CMR 1985].
1.3 POTENTIAL FOR OCCUPATIONAL EXPOSURE
Data on worldwide occupational exposures to acrylamide are unavailable. However, since exposure 
occurs during aciylamide production and use, the potential for occupational exposure exists in all 
countries that produce or import acrylamide. The National Institute for Occupational Safety and 
Health (NIOSH) estimates that more than 10,000 U.S. workers were potentially exposed to 
acrylamide monomer during the period 1981-83, either in acrylamide manufacturing and processing 
or in grouting operations (particularly in sewer grouting) [NIOSH 1983]. Other workers that are 
potentially exposed to variable and intermittent airborne concentrations and possible dermal contact 
with acrylamide are the researchers and technicians involved in the preparation of polyacrylamide
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Table 1. Identifying information and chemical and 
physical properties o f acryiamide*
Item Description
CAS registry number 7 9 -0 6 -1
RTECS number AS3325000
Synonyms Acryiamide monomer,
Formula (structure)
acrylic amide, 
propenamide 
C3H5NO (CH2= C H C (= 0 )N H 2)
Molecular weight 71.08
Physical form White, crystalline solid
Melting point 84.5 ± 0.3°C (184.1° ± 0.5°F)
Boiling point 125°C at 25 mm H g (decomposes on
Density
boiling)
1.122 g/cm 3 at 30°C (86°F)
Vapor pressure 0.007 mm H g at 25°C (  77°F),
Conversion factors
0.033 mm H g at 40°C (104°F), 
0.070 mm H g at 50°C (122°F) 
1 ppm »  2.9 m g/m 3 at 25°C,
Solubilities (in g/100 ml at 30°C): 
Acetone
1 m g/m 3 ~  0.34 ppm at 25°C 
63.1
Acetonitrile 39.6
Benzene 0.346
Carbon tetrachloride 0.038
Chloroform 2.66
1,2-Dichloroethane 1.50
Dimethylform amide 119
Dimethylsulfoxide 124
Dioxane 30
Ethanol 86.2
Ethylacetate 12.6
n-Heptane 0.007
Methanol 155
Pyridine 61.9
Water 215.5
’Adapted from American Cyanamid Company [1969] and NIOSH [1976].
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Table 2. Physical properties of a 50% aqueous solution of acrylamide*
Property Value
Assay (WT% acrylamide) 48-62
pH 5 .0 -6 3
Polymer, max % 0.05
Viscosity 2.71 centipoise at 25°C (77°F)
Specific gravity 1.0412 at 25°C (77°F)
Melting point 8°-13°C (47°-54°F)
Boiling point 99°-104°C (210°-220°F)
Vapor pressure 18 mm Hg at 23°C (73.4°F),
Specific heat
(20°-50°C, range)
29.8 nun H g at 31.2°C (88.2°F), 
43.4 mm H g at 37.8°C (100°F), 
92.7 mm Hg at 52.7°C (126.9°F), 
209.5 mm H g at 70.5°C (158.9°F)
0.83 cal/(g-deg)
Heat of dilution to 20 WT% 1.1 cal/g  of solution (or 2.0 Btu/lb
Heat o f polymerization
of solution) [exothermic] 
20.4 kcal/g mole [exothermic]
Heat o f melting (solution) 59.2 cal/g  (106.5 Btu/lb)
Flammability Nonflammable
’ Adapted from GCA [1980].
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gels. The U.S. Environmental Protection Agency (EPA) [EPA 1988a] estimates that 100,000 to
200,000 of these U.S. workers have the potential for exposure.
Because acrylamide is produced by catalytic or sulfuric acid hydration of acrylonitrile (identified by 
the International Agency for Research on Cancer [IARC] as a probable human carcinogen [IARC 
1987]), acrylamide production workers may also be exposed to acrylonitrile.
Evaluation of exposure data from industrial settings [Hills and Greife 1986] indicates that in all four 
U.S. acrylamide production plants, airborne concentrations were generally below 0.3 mg/m3—the 
occupational exposure limit set by many countries (see the Appendix).
Of the ninety 8-hr time-weighted average (TWA) personal samples collected in the four U.S. 
acrylamide production plants, only two samples from one of the plants were above 0.3 mg/m3 (0.38 
and 0.39 mg/m3). However, many samples exceeded the current Occupational Safety and Health 
Administration (OSHA) permissible exposure limit (PEL) of 0.03 mg/m3 adopted in 1989 [54 Fed. 
Reg. 2332 (1989)].
Hills and Greife [1986] noted that of the cases they reviewed, most adverse health effects were 
caused by dermal or oral exposures to acrylamide. The major routes of occupational exposure 
appear to be dermal absorption of the acrylamide monomers from solution and inhalation of the 
dry monomer or aerosols of acrylamide solution [Hills and Greife 1986; EPA 1987; He et al. 1989]. 
An EPA study of sewer workers involved in grouting operations indicated high dermal exposure 
estimates ranging from 0.6 to 5.0 mg/hr [EPA 1987]. Studies evaluating occupational exposures to 
acrylamide monomer indicate that dermal exposures may be more important with regard to the 
total body intake than inhalation exposures [Hills and Greife 1986; EPA 1988a; He et al. 1989].
1.4 EXISTING STANDARDS AND RECOMMENDATIONS
Many international standards for workplace exposures to acrylamide are 0.3 mg/m3 with a skin 
notation. The current American Conference of Governmental Hygienists (ACGIH) threshold limit 
value (TLV») [ACGIH 1989] and the current OSHA PEL [29 CFR 1910.1000] are both 0.03 mg/m3. 
The current Swedish occupational exposure limit is 0.3 mg/m3 with a skin notation and a short-term 
exposure limit (STEL) of 0.9 mg/m3. See the Appendix for a list of the occupational exposure limits 
for airborne acrylamide in various countries and a discussion of the bases for recommendations that 
depart from the frequently cited limit of 0.3 mg/m3.
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2.1 METABOLISM
Acrylamide [CH2=CHC(= 0)N H 2] is a small organic molecule that is very soluble in water and can 
react at both its amide group and its double-bond vinyl group. This reactivity and ease of transport 
may account for the toxic effects of acrylamide. Studies show that the toxicokinetics and tissue 
distribution of acrylamide are not significantly dependent on the dose and route of exposure. The 
parent compound is rapidly eliminated from the tissues. The uptake, distribution, biotrans­
formation, and elimination, which are summarized below, have been discussed in detail by Dearfield 
et al. [1988].
2.1.1 Uptake
No studies were found on the absorption of acrylamide by inhalation. All animal studies involved 
either oral or dermal exposure, and intraperitoneal (i.p.) or intravenous (i.v.) dosing. The uptake 
of acrylamide through the gastrointestinal tract of rats was rapid and complete, as indicated by 
similar excretion profiles of the chemical whether it was administered by i.v. injection or by gavage 
[Miller et al. 1982]. Dermal absorption in the rat is less than complete. By comparing blood 
concentrations after i.v. or dermal administration of acrylamide, Ramsey et al. [1984] calculated that 
25% of the applied doses (2 or 50 mg/kg) of acrylamide were absorbed through the skin of rats 
during the first 24 hr. Frantz et al. [1985] reported that 26% of a 0.5% aqueous solution of 
acrylamide was absorbed through the skin of rats in 24 hr and that, after the skin was washed, an 
additional 35% remained in the skin. The data from in vitro experiments were similar [Frantz et 
al. 1985]. These researchers used excised skin preparations to show that 67% of the applied 
acrylamide was either absorbed or available for absorption (that is, 54% was absorbed and 13% 
remained in the skin after washing).
2.1.2 Distribution and Toxicokinetics
After rats received various doses of acrylamide (0.5 to 100 mg/kg) by i.v. or oral administration, 
the 14C-labeled chemical quickly distributed throughout the body [Hashimoto and Aldridge 1970; 
Edwards 1975; Miller et al. 1982; Ramsey et al. 1984]. Approximately 12% of the 14C-labeled 
chemical rapidly accumulated in red blood cells [Hashimoto and Aldridge 1970; Miller et al. 1982], 
and high levels persisted for at least 10 days. ITiis persistence has been postulated to result from 
the reaction of acrylamide with sulfhydryl moieties present in hemoglobin [Hashimoto and Aldridge 
1970]. Miller et al. [1982] reported that high percentages of the wC-labeled chemical were found 
in muscle (48%), skin (15%), blood (12%), and liver (7%), whereas the neural tissues (brain, spinal
5
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cord, and sciatic nerve) contained less than 1%. However, when the data were expressed as 
micromoles (¿tmoles) of acrylamide/g of tissue, the concentrations of acrylamide in the tissues were 
similar. In the neural tissues of rats there appears to be no preferential bioconcentration of 
acrylamide and/or its metabolites that can account for its neurotoxic effects [Miller et al. 1982].
Acrylamide has also been reported to distribute readily in the tissues of other animal species. For 
example, acrylamide was found in the blood, brain, heart, liver, kidneys, and lungs of miniature 
swine and beagle dogs, with the highest concentrations found in the liver and kidneys [Ikeda et al.
1985]. Because the authors did not analyze skin, muscle, and other tissues, it is difficult to compare 
the results with those reported by Miller et al. [1982]. In addition, autoradiographic studies have 
demonstrated a similar distribution of acrylamide in male and pregnant female mice [Marlowe et 
al. 1986]. Acrylamide was found to cross the placentas of rats, rabbits, dogs, pigs, and mice and to 
be uniformly distributed in those fetuses [Ikeda et al. 1983, 1985; Marlowe et al. 1986].
Ramsey et al. [1984] have examined the effects of multiple oral doses on tissue distribution. When 
rats were given acrylamide at 0.05 or 30 mg/kg for 13 consecutive days, the ratio of the 14C-labeled 
chemical in the tissues at the two doses was proportional to the ratio of the doses administered 
(that is, 600) except in the red blood cells (304), blood plasma (1,089), and testes (934). These data 
demonstrate that multiple doses of acrylamide do not greatly alter its distribution except at those 
three sites.
2.1.3 Biotransformation and Elimination
Conjugation with glutathione (GSH) is the major route for the biotransformation of acrylamide. 
Several studies show that acrylamide depletes GSH [Hashimoto and Aldridge 1970; Edwards 1975; 
Srivastava et al. 1983] and that hepatic GSH-S-transferases catalyze the reaction of acrylamide with 
GSH [Dixit et al. 1981]. The major urinary metabolite of acrylamide is N-acetyl-S-(3-amino-3- 
oxypropyl) cysteine, and it accounts for approximately 50% of the applied dose in rats [Miller et al. 
1982; Ramsey et al. 1984]. Three other unidentified, nonsulfhydryl urinary metabolites accounted 
for an additional 14% [Miller et al. 1982]. When acrylamide was labeled at the carbonyl carbon, 
it was found that 4% to 6% of the labeled chemical was eliminated as C 02 [Hashimoto and 
Aldridge 1970; Ramsey et al. 1984]. Because 15% of the dose appeared in the bile within 6 hr but 
only 6% was excreted in the feces, it was concluded that acrylamide (or its metabolites) underwent 
enterohepatic circulation [Miller et al. 1982].
Miller et al. [1982] used rats in a detailed study of the pharmacokinetics and distribution of 
acrylamide, both as the parent compound and as the total “¿-labeled chemical after an i.v. dose of 
10 mg/kg. The elimination of the parent acrylamide was represented by a single compartment 
model. In the blood, the parent compound had a half-life of 1.7 hr, and the clearance of the 
unmetabolized acrylamide from all other tissues but the testes was similar. The testes showed a 
delay in the time necessary to reach peak concentration—an event attributed to their fat content. 
After the peak was attained, the parent acrylamide was cleared from the testes in a manner similar 
to that for other tissues [Miller et al. 1982].
The distribution and the elimination of the total 14C-labeled chemical (representing acrylamide and 
its metabolites) was slower than that of the parent compound and was best represented by a 
biphasic curve [Miller et al. 1982]. In addition, four tissues (liver, kidney, fat, and testes)
6
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demonstrated absorptive phases for the total 14C-labeled chemical. Since no absorption phases were 
noted for the parent acrylamide in the liver and kidney, the increases in the 14C-labeled chemical 
in these two tissues were attributed to metabolite accumulation. The higher lipid content of the fat 
and testes and the polar nature of acrylamide were reported by Miller et al. [1982] to have delayed 
the absorption in these two tissues. The initial portion (half-life of 5 hr) of the biphasic curve was 
attributed to the metabolism of acrylamide and the binding of its metabolites to biological 
macromolecules, since only 2% of the total dose of administered acrylamide was excreted as the 
parent compound. The terminal portion (half-life of 8 days) of the biphasic curve was thought to 
be the result of the release of acrylamide metabolites from tissue depots and the degradation of 
acrylamide-protein adducts [Miller et al. 1982]. Support for these suppositions was provided by 
Ramsey et al. [1984], who analyzed urine, plasma, and tissue samples in male Fisher 344 rats 
following either i.v., gavage, or dermal administration of 14C-labeled acrylamide. Their data 
indicated that the initial phase was due to the loss of the parent compound and that the latter phase 
resulted from the clearance of acrylamide metabolites.
Because acrylamide affects reproduction, the very slow release of acrylamide or its metabolites from 
the testes is of particular interest. Although the fat content of the testes may have decreased the 
uptake of the parent acrylamide, it would not appear to account for its slow excretion. It is possible 
that acrylamide is metabolized and binds to constituents of the testes. Marlowe et al. [1986] 
reported that radioactivity appeared in the testes 1 hr after administration and migrated to the 
seminiferous tubules and head of the epididymis after 9 hr. After 9 days, radioactivity remained 
only in the tail of the epididymis and in the epithelium of the penis. Marlow et al. [1986] correlated 
this movement with that of the spermatids.
2.1.4 Factors That Can Affect Metabolism
Studies of the effects of altering microsomal mixed-function oxidase activity on the expression of 
acrylamide-induced neuropathy have given disparate results.
Pretreatment of rats with phenobarbital (PB) or DDT [Kaplan et al. 1973] or mice with PB 
[Hashimoto et al. 1981] reduced or delayed the neurological dysfunction caused by acrylamide 
administered by i.p. injection. However, Srivastava et al. [1985] found that pretreatment of rats with 
PB or DDT decreased the time necessary for onset of acrylamide-induced hind-limb paralysis. This 
disparity does not appear to be due to variations in experimental protocol, but it may be explained 
by differences in the animal strains.
The results of using drug metabolism inhibitors are difficult to interpret. For example, SKF 525A 
(which inhibits microsomal oxidation) has been reported to prevent acrylamide-induced enhance­
ment of striatal dopamine receptor activity [Agrawal et al. 1981] and to increase the acute toxicity 
of acrylamide in rats [Kaplan et al. 1973], whereas cobalt chloride has been shown to cause a 
significant delay in the development of hindlimb paralysis in rats [Srivastava et al. 1985]. Presently, 
no correlation exists between the effects of modifying microsomal metabolism of acrylamide and 
expression of its toxic effects. Accordingly, identification of metabolic factors important in the toxic 
manifestations of acrylamide is not possible. Khanna et al. [1988] studied the role of protein 
deficiency on the neurobehavioral effects of acrylamide in rat pups exposed during pregnancy and 
early infancy. They demonstrated that acrylamide was more toxic in protein-deficient animals 
because it decreased the dopamine and benzodiazepam receptor binding and delayed the 
development of reflexes and other physical milestones in pups.
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2.2 TOXICOLOGIC MECHANISMS
Because the most noticeable and earliest detectable effects of acrylamide exposures are neurological 
effects, numerous studies have attempted to find the mechanism of its action in neural tissues. 
Several mechanisms may account for the effects of acrylamide on the peripheral and central nervous 
systems. Biochemical studies indicate that acrylamide affects the proteins responsible for normal 
functioning of neural tissues. Berti-Mattera et al. [1986] found that acrylamide alters axonal protein 
phosphorylation and polyphosphoinositide metabolism. Another study revealed that acrylamide 
treatment in vivo induces changes in the composition of fast-transported proteins that are similar 
to those seen after axonotomy [Bisby and Redshaw 1987]. In vitro treatment of PtKl cells by 
acrylamide resulted in rapid dephosphorylation of keratins [Eckert and Yeagle 1988]. Many of 
these changes may be explained by altered phosphorylation of cytoskeletal proteins [Howland and 
Ali 1986]. This phosphorylation may result from the binding of acrylamide to proteins, which has 
been demonstrated in vitro with bovine serum albumin (BSA) [Dixit et al. 1986]. Husain et al. 
[1986,1987] found that acrylamide inhibits succinic dehydrogenase (SDH) activity in mitochondrial 
preparations from rat brain and causes changes in levels of biogenic amines and activities of 
monoamine oxidase and acetylcholine esterase. Biochemical changes may be responsible for the 
functional changes observed in neural tissues—for example, changes in membrane capacitance and 
sodium permeability [Brismar et al. 1987], changes in primary afferent terminal function [De Rojas 
and Goldstein 1987], reduction of neurofilament transport in rat sciatic nerve [Gold 1987], and 
alterations in spinal cord reflexes [Goldstein and Fincher 1986].
In light of the reported genotoxicity and carcinogenicity of acrylamide (see Sections 4 and 5), 
information on the binding of this compound to DNA is of considerable interest. Binding of 
acrylamide to DNA has been demonstrated to occur in the lung, liver, testes, stomach, and skin of 
mice 6 hr after oral or dermal administration of acrylamide [Carlson and Weaver 1985]. Whether 
or not the parent acrylamide or a metabolite was responsible for the in vivo acrylamide-DNA 
adducts, it was demonstrated that acrylamide can alkylate DNA in an in vitro system [Solomon et 
al. 1985]. Because the yield of alkylated DNA after 40 days of incubation was low (approximately 
10%), the relevance of these in vitro binding studies to the in vivo DNA-binding studies reported 
by Carlson and Weaver [1985] remains to be established. However, the fact that acrylamide has 
been shown to interact with genetic material may have implications for its genotoxic and 
carcinogenic effects.
2.3 TOXICITY IN HUMANS AND ANIMALS
Polyacrylamide products are generally considered nontoxic [McCollister et al. 1965]. Human health 
hazards related to acrylamide monomer exposures are neurotoxicity, developmental and 
reproductive effects, genotoxicity, and carcinogenicity.
2.3.1 Neurotoxic Effects
The neurologic effects of acrylamide exposures were extensively reviewed in the National Institute 
for Occupational Safety and Health (NIOSH) criteria document on acrylamide [NIOSH 1976].
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Exposure to acrylamide can produce serious neurotoxic effects in humans and animals [Spencer and 
Schaumburg 1975; Tilson 1981; Miller and Spencer 1985; O’Donoughue 1985]. These include 
peripheral nerve damage (paresthesia of the hands and feet, muscle weakness, ataxia, and decreased 
tendon reflexes) and central nervous system (CNS) effects (drowsiness, tremors, slurred speech, and 
hallucinations). Although most of these effects ceased after the individual was removed from 
exposure, some severely affected persons did not recover completely, indicating irreversible effects 
[Miller and Spencer 1985].
Spencer and Schaumburg [1974] reviewed acrylamide neurotoxicity in humans. The earliest and 
most obvious signs of local acrylamide contact are erythema and peeling of the palms caused by 
contact with acrylamide solution. This contact dermatitis precedes neurological symptoms by several 
weeks. Shortly after the appearance of contact dermatitis, exposed individuals may notice excessive 
fatigue, weight loss, and somnolence [Garland and Patterson 1967]. The neurological symptoms 
occur after chronic exposures. Exposed individuals experience unsteadiness, muscle weakness, and 
paresthesia, with numbness in the hands and/or feet. Sensory symptoms frequently precede overt 
motor signs [Takahashi et al. 1971]. If individuals are removed from exposure sources, signs of 
peripheral neuropathy gradually disappear [He et al. 1989]. In less severely affected individuals, 
complete recovery may occur within 2 to 12 months [Garland and Patterson 1967].
A recent study described the neurological and electroneuromyographic assessment of the effects of 
acrylamide on occupationally exposed workers in China [He et al. 1989]. The authors reported that 
more than 90 cases of acrylamide intoxication have occurred in China in the past 5 years as a result 
of increased acrylamide exposures in a number of small township-run or village-owned industries. 
He et al. [1989] investigated occupational exposures and toxic effects of exposure to acrylamide in 
a factory that began acrylamide and polyacrylamide production in 1984. The initial air 
concentrations of acrylamide were measured at 5.6 to 9.0 mg/m3 during an exceptional increase in 
production from March to June 1985. After renovation of the factory in July 1985, the air 
concentrations dropped to an average of 0.03 mg/m3. Heavy skin contamination by aqueous 
acrylamide monomer was common among the exposed workers because of inadequate personal 
protection, lack of awareness of acrylamide toxicity, and unsatisfactory personal hygiene. Water in 
which three exposed workers washed their hands contained 410 mg acrylamide/Uter.
Seventy-one exposed workers (45 men and 26 women) were studied in October 1985 [He et al. 
1989]. They had been exposed to variable concentrations of acrylamide for 1 to 18 months. Fifty- 
one unexposed blue collar workers from the same town (33 men and 18 women) served as a 
reference group; nobody in this group suffered from measurable neurological disease. All subjects 
were interviewed with the aid of a structured questionnaire to obtain information on demographic 
factors, occupational history, symptoms, past illnesses, and family history. Physical and neurological 
examinations, visual acuity and visual field testing, skin temperature measurements, electro­
cardiography, and electroencephalography were performed. The laboratory studies included routine 
blood and urine tests, liver function, serum hepatitis B surface antigen, serum glucuronidase, and 
immunoglobulins. Electroneuromyographic examinations were performed in 63 exposed and 48 
unexposed workers. The exposed workers reported numerous symptoms that were nonexistent or 
rarely reported in the unexposed group. These included skin peeling from the hands, numbness in 
the hands and feet, lassitude, sleepiness, muscle weakness, clumsiness of the hands, anorexia, 
unsteady gait, coldness of the hands and feet, stumbling, falling, and difficulty in grasping. The 
initial symptoms were peeling of the skin and excessive sweating of the hands, which were mainly 
due to topical contamination by aqueous acrylamide. Muscle weakness of the legs and numbness 
and tingling of the hands and feet (indicating an involvement of the peripheral nervous system)
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appeared in one-fifth of the exposed workers after 3 to 10 months of exposure. Nine workers 
developed lassitude, sleepiness, anorexia, and loss of body weight 1 month after initial symptoms; 
the symptoms progressed to inability to hold things tightly, unsteadiness in walking, and difficulty 
in lifting legs when climbing stairs. Three of the nine were found to have horizontal nystagmus, 
truncal ataxia, and clumsiness of the hands when they were admitted to a hospital in May 1985. 
They showed improvement in cerebellar function a month later but began losing tendon reflexes and 
their sensation of vibration. When interviewed in October 1985, these individuals showed con­
siderable recovery.
Electroneuromyographic studies of the 69 acrylamide workers showed a prolonged duration of 
motor unit potentials in 40 workers and an increase of polyphasic potentials in 29 workers. In 25 
of these 40 workers, there were no signs of neuropathology, such as impairment of distal sensation 
or reflexes. This finding suggests that a partial denervation of the distal muscles caused by axonal 
degeneration of peripheral nerves could be a subclinical abnormality in workers exposed to 
acrylamide. He et al. [1989] suggested that electroneuromyographic changes could be used for early 
detection of acrylamide neurotoxicity. Most of the workers diagnosed as suffering from 
occupational acrylamide intoxication handled a 27% to 30% aqueous solution of acrylamide. Their 
exposure to aqueous solutions of acrylamide suggests that dermal contact may have been the main 
route of exposure.
Several subchronic and chronic animal studies have demonstrated that the neurotoxic effects of 
acrylamide exposures in animals are similar to the effects in humans [Schaumburg and Spencer 
1979; Burek et al. 1980]. Hind-limb ataxia appears to be one of the first symptoms of neuropathy 
in dogs [Satchell and McLoad 1981; Hersch et al. 1989], cats [Spencer and Schaumburg 1977b], 
monkeys [Merigan et al. 1982], and rats [Spencer and Schaumburg 1976a, 1977b; Tilson et al. 1979].
2.3.2 Developmental and Reproductive Effects
Data on developmental and reproductive effects in animals are summarized in Tables 3 and 4. No 
such data are available for humans. Acrylamide exposure affected both fetal and postnatal 
development in mouse and rat offspring when dams were orally dosed during pregnancy [American 
Cyanamid Company 1980; Zenick et al. 1986]. Neurotoxic effects occurred in neonates when the 
dam drank water containing acrylamide concentrations that were not toxic to her [American 
Cyanamid Company 1980].
Reproduction is also affected by acrylamide exposure. Testosterone levels were depressed in rats 
[Ali et al. 1983], and fertility decreased in male mice after oral exposure to acrylamide in drinking 
water [Sakamoto and Hashimoto 1986]. Degeneration of testicular epithelial tissue in male mice 
dosed by gavage [Hashimoto et al. 1981] has been observed as well as dominant lethal effects in 
male rats exposed through drinking water [Smith et al. 1986] and mice treated i.p. [Shelby et al. 
1986]. Oral exposure of male or female mice and rats to acrylamide in drinking water caused an 
increased resorption rate [Nalco Chemical Company 1987; Sakamoto and Hashimoto 1986].
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Table 3. Reproductive effects of acrylamide exposure in female ra ts and mice and developmental effects in their offspring*
Maternal Developmental Observed effects
Type of study Species, route,
and reference and dosage LOEL+ NOEL+ LOEL NOEL Maternal Developmental
Developmental
toxicity
[Edwards 1976]
Reproduction 
and fertility 
[Zenick et al. 
1986]
Developmental/ 
neonatal 
[Walden et al. 
1981]
Porton rat; 
oral—diet;
0 ppm, 200 ppm, 
or 20 m g/kg  
per day, gd+ 0-22; 
400 ppm or 40 m g/kg  
per day, gd 0-20;
100 m g/kg (i.v.), gd 9
Long Evans rat; 
oral— drinking water; 
0, 25, 50, 100 ppm 
for 2 weeks before 
mating and through­
out gestation and 
lactation
Fischer 344 rat; 
oral—gavage;
20 m g/kg per day, 
gd 7-16
200 ppm+ 
[20 m g/kg  
per day]+
400 ppm 
[400 m g/kg  
per day]
50 ppm 25 ppm 50 ppm 25 ppm
20 m g/kg 
per day
Developmental Sprague-Dawley rat; 50 ppm 25 ppm D ose
toxicity
(1-generation
reproductive)
[American
Cyanamid
Company, 1980]
oral— diet; 0, 25, 
50 ppm or 0, 2.5, 
5.0 m g/kg per day 
3 weeks before 
mating, gd 1-19
unspeci­
fied
D ose
unspeci­
fied
Ataxia; abnormal 
gait
Decreased body 
weight (50 ppm)
Decreased fluid 
intake (50 ppm)
Increased hind-limb 
splaying (100 ppm)
None reported
Decreased body 
weight gain; slight 
alopecia
Nerve fiber degen­
eration in sciatic 
and optic nerves
None\ it was shown, 
however, that 
acrylamide readily 
crosses the 
placenta
Decreased birth 
weight
Decreased body 
weight gain in pups 
through day 42
Changes in various 
intestinal enzyme 
concentrations meas­
ured in the neonate
Wallerian degenera­
tion of tibial nerve, 
unilateral optic 
nerve degeneration 
(dose unspecified)
(Continued)
See footnotes at end of table.
Table 3 (Continued). Reproductive effects of acrylamide exposure in female ra ts  and mice and developmental effects in their offspring*
Maternal Developmental Observed effects
Type of study Species, route,
and reference and dosage LOEL+ N O EL+ LOEL NOEL Maternal Developmental
1-Generation 
reproductive 
[Nalco Chemical 
Co. 1987]
Fischer 344 rat; 
oral—drinking 
water; 0, 0.5,
2.0, 5.0 m g/kg per 
day for 10 weeks 
throughout gestation 
and lactation
2.0 m g/kg  
per day
0.5 m g/kg 5.0 m g/kg  
per day per day
2.0 m g/kg  
per day
Reproductive 
toxicity assay 
[Sakamoto and 
Hashimoto 1986]
ddY mouse, 
oral— drinking 
water; 0 -5  mM  
for 4 -6  weeks
1.2 m M + or 
18.6 m g/kg  
per day
1.2 mM or 
18.6 m g/kg  
per day
Increased
peripheral
neuropathy
Decreased body 
weight
Decreased body 
weight gain
Decreased number 
of litters 
(fecundity index)
Increased pre­
implantation loss 
(5.0 m g/kg per day)
Increased number 
of resorptions 
per dam
Slight hind-limb 
weakness
Increased 
resorptions per litter
Decreased litter 
size
None reported
* Adapted from EPA [1987].
+Abbreviations: gd = gestation day; LOEL = lowest-observable-effect level; NOEL = no-observable-effect level; m g/kg per day = milligrams per 
kilogram of body weight per day, mM = millimolar (concentration of acrylamide in drinking water); ppm = parts per million.
Table 4. Reproductive effects of acrylamide exposure in male ra ts and mice
Type of study Species, route,
and reference and dosage LOEL+ NOEL+ Observed effects
Dominant 
lethal and 
1-generation 
reproductive 
[Nalco Chemical 
Co. 1987]
Testicular 
effects 
[Hashimoto 
et al. 1981]
Dominant
lethal
[Smith et al. 
1986]
Fisher 344 rat; 
oral— drinking water; 
0, 0.5, 2.0, 5.0 m g/kg  
per day for 10 weeks
2.0 m g/kg  
per day+
0.5 m g/kg  
per day
ddY mouse; 
oral—gavage;
0, 35.5 m g/kg  
2x/w k for 8-10 weeks; 
avg. daily dose =
10.1 m g/kg
Long Evans rat; 
oral—drinking water;
0, 15, 30, 60 ppm+ 
or 0, 1.5, 2.8, 5.8 m g/kg  
per day for 80 days
35.5 m g/kg  
per day
10.1 m g/kg
2.8 m g/kg  
per day
15 m g/kg  
per day
Increased peripheral neuropathy
Decreased body weight
Decreased body weight gain
Decreased number of litters 
(fecundity index)
Increased preimplantation loss 
(5.0 m g/kg per day)
Degeneration of testicular 
epithelia
Weakness and ataxia in hind 
limbs
Increased preimplantation loss 
(highest dose only)
Increased postimplantation loss
Reproductive 
toxicity assay 
[Sakamoto and 
Hashimoto
1986]
ddY mouse; 
oral—drinking water; 
0 3 , 0.6, 0 .9 ,1 .2  mM  
for 4-6  weeks
0.6 m M + 
or
8.8 m g/kg  
per day
0 3  mM  
or
4.2 m g/kg  
per day
Decreased fertility rate
Decreased number fetuses/dam
Increased number 
resorptions/dam
(Continued)
See footnotes at end of table.
Table 4 (Continued). Reproductive effects of acrylamide exposure in male ra ts  and mice*
Type of study 
and reference
Species, route, 
and dosage LOEL+ NOEL+ Observed effects
Reproduction Long Evans rat; 100 ppm 50 ppm Decreased copulatory
and fertility oral— drinking water; [7.9 m g/kg [4.2 m g/kg performance
[Zenick et al. 
1986]
male: 0, 50, 100, 200 ppm 
or 0, 4.2, 7.9, 11.6 m g/kg  
per day for 10 weeks
per day] per day]
Increased hind-limb splaying
Dominant Long Evans rat; 30 mg/kg 15 mg/kg Increased preimplantation loss
lethal
[Sublet et al. 
1986]
oral— drinking water;
0, 5, 15, 30, 45, 60 m g/kg  
per day for 5 days
per day per day
Increased postimplantation loss
Effects seen primarily in weeks 
1-3 post mating
Testosterone Fischer 344 rat; 20 mg/kg 10 mg/kg Dose-dependent decrease of
assay 
[Ali et al. 
1983]
intraperitoneal;
0, 10, 20 m g/kg  
per day for 20 days
per day per day testosterone and prolactin
Dominant
lethal
[Shelby et al. 
1986]
C3H X101 hybrid 
mouse; i.p.
125 m g/kg  
or 5* 50 m g/kg  
per day
50 mg/kg  
per day
Increased postimplantation loss
* Adapted from EPA [1987].
+Abbreviations: LOEL = lowest-observable-effect level; NOEL = no-observable-effect level; m g/kg per day = milligrams per kilogram of 
body weight per day, mM = millimolar (concentration of acrylamide in drinking water); ppm = parts per million.
2 Toxicology
2.4 GENOTOXIC EFFECTS
The major concern about the genotoxicity of acrylamide is its clastogenic activity (that is, 
chromosomal breakage and other chromosomal abnormalities). The clastogenic effect of acrylamide 
appears more pronounced in the germ cells compared with somatic cells. The interaction with 
germinal tissues suggests the possible heritabUity of acrylamide-induced DNA alterations. 
Acrylamide has been shown to be a clastogenic agent both in vivo and in vitro [Moore et al. 1987].
Reports suggest that acrylamide binds to DNA [Carlson and Weaver 1985], induces DNA damage 
and repair effects, and causes in vitro cell transformation [Banerjee and Segal 1986]. In a recent 
study % Backer et al. [1989], various cytogenetic endpoints in both somatic and germ cells from 
acrylamide-treated male C57BL/6J mice were evaluated. Sister chromatid exchanges and 
micronuclei (but not chromosomal aberrations) were induced in spleen cells; synaptonemal complex 
irregularities (asynopsis) (but not chromosomal aberrations) were induced in germ cells.
2.4.1 Gene Mutation Assays
Acrylamide does not appear to induce gene mutations in the three types of gene mutation assays 
examined; the Salmonella/ mammalian activation assay [Bull et al. 1984a; Lijinsky and Andrews 
1980; Hashimoto and Tanii 1985], the CHO/HPRT mutation assay [American Cyanamid 1985], and 
the Drosophila sex-linked recessive lethal assay [American Cyanamid 1985]. The mouse lymphoma 
mutation data suggest that acrylamide may induce mutations in an eukaryotic gene mutation assay 
[Moore et al. 1987], but these data may reflect a clastogenic event associated with the predominant 
formation of small colonies. It may be relevant that the CHO subclone generally used in the 
CHO/HPRT mutation assay does not appear to be sensitive to clastogens [Hsie et al. 1986].
2.4.2 Chromosomal Assays
Studies that have examined the chromosomal effects of acrylamide have confirmed its clastogenic 
potential. This effect appears to be more pronounced in the germ cells than in somatic cells. The 
suggestive reciprocal translocation results raise the possibility that acrylamide-induced alterations 
to DNA may be transmissible to future generations. A study of heritable translocation in mice 
[Shelby et al. 1987] demonstrated that acrylamide is an effective inducer of translocations in 
postmeiotic germ cells. This result demonstrates that acrylamide may be capable of affecting 
heritable germ cells in a mammalian system.
In vivo and in vitro results suggest that acrylamide may induce aneuploidy. It is uncertain whether 
metabolic activation is required for acrylamide to exert its genotoxic effects, because most of the 
clastogenic activity was noted in in vivo studies. In vitro studies with human lymphocytes in which 
clastogenicity was observed were performed without activation [IHE 1985]. However, the metabolic 
activating capability of lymphocytes has not been totally explored, and it is known that lymphocytes 
are capable of activating chemicals such as cyclophosphamide to genotoxic forms [Waalkens et al. 
1981]. The mouse lymphoma results demonstrate that acrylamide induces aberrations without 
activation [Moore et al. 1987].
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2.5 CARCINOGENIC EFFECTS
2.5.1 Epidemiologic Findings
Collins et al. [1989] studied the mortality of workers in acrylamide production plants. This study 
was performed by scientists at major production plants. Mortality was tracked for a cohort of 8,854 
males from 1925 to 1983. This cohort (2,293 of whom were exposed to acrylamide) consisted of four 
plant populations in the United States and the Netherlands. Followup was completed for 95% of 
the cohort. At the end of the study 2,148 individuals were deceased, and death certificates were 
obtained for 95%. The underlying cause of death was coded by a nosologist. Exposure estimates 
were developed for all jobs at each of the four plants using exposure data collected at each plant 
and information obtained from plant personnel who had knowledge of past jobs and processes. 
Exposure to acrylamide was defined as a cumulative exposure greater than 0.001 mg/m3-years, which 
is approximately equivalent to a 1-day exposure to an average concentration of 0.3 mg/m3. Data 
on smoking history were available for only a third of the cohort. Standardized mortality ratios 
(SMRs) and internally standardized rate ratios were employed to estimate the risk.
According to the authors, a particular strength of their study was the ability to detect a 25% 
increase in total cancer, a 50% increase in respiratory cancer, and a threefold increase in brain and 
other central nervous system cancers based on a two-tailed, 5% significance level with a power of 
80%.
The SMRs for all causes for both exposed and unexposed groups were significantly less than 
expected, which may be the result of both initial selection and the ongoing benefits of employment 
(i.e., the healthy worker effect). An excess of total cancer deaths was not observed among the 
exposed workers. A slight increase in cancer of the respiratory system (30 observed versus 26.3 
expected) was not statistically significant. Analyses of trends by cumulative exposure showed no 
increased risk of mortality with increasing exposure. Because smoking history was obtained for only 
a third of the cohort, it was impossible to determine whether smoking habits had confounded the 
results.
Sobel et al. [1986] examined mortality in a group of 371 workers assigned to acrylamide monomer 
or polyacrylamide operations. Exposure to acrylamide was categorized on the basis of a review of 
job classifications. Before 1957, personal TWA exposures to acrylamide in the monomer production 
areas were 0.1 to 1.0 mg/m3. The data from 1957 to 1970 indicated that exposures to acrylamide 
were 0.1 to 0.6 mg/m3. After 1970, personal exposures to acrylamide were <0.1 mg/m3 for all job 
classifications. Associated with the production of acrylamide monomer is the potential for exposure 
to acrylonitrile. The possible confounding effect of this exposure was not formally addressed in this 
study; but in a previous epidemiologic study [Ott et al. 1980], no effects could be directly related 
to acrylonitrile under the conditions of exposure. The total number of deaths from malignancies 
was slightly elevated (11 observed versus 7.9 expected [p<0.05]), but this result was apparently due 
to the excess in a subgroup that was also exposed to organic dyes [Sobel et al. 1986]. Overall, the 
results did not indicate an excess of cancers from exposures to acrylamide. However, these results 
may be due to the small cohort size, limited followup, and short duration of exposure (274 workers 
were exposed for less than 5 years). Given the size of the total cohort and the period of 
observation, the study had only an 80% likelihood (power) of detecting a twofold or greater increase 
in total cancer incidence.
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2.5.2 Evidence of Carcinogenicity in Animals
Studies in rats and mice indicate that acrylamide is an animal carcinogen [Bull et al. 1984a, 1984b; 
Johnson et al. 1986]. Acrylamide was tested for skin-tumor-initiating activity in Senear mice and 
for the ability to induce lung adenomas in A/J mice [Bull et al. 1984a]. In a mouse skin 
initiation-promotion assay, 6- to 8-week old female Senear mice were divided into groups of 40 and 
treated topically, by gavage, or by i.p. injection with acrylamide dissolved in water. Acrylamide was 
tested at doses of 12.5, 25, and 50 mg/kg for six applications by the three routes over a 2-week 
period, resulting in total doses of 75, 150, and 300 mg/kg. Ethyl carbamate, a known initiator, was 
used for a comparison in doses of 30,100, and 300 mg/kg in one application administered topically, 
by gavage, or i.p. A  tumor promotion regimen was started 2 weeks after the last of the 
tumor-initiating doses of acrylamide. One microgram of 12-0-tetradecanoyl-phorbol-13-acetate 
(TPA), a known tumor promoter, was applied topically 3 times/week for 20 weeks. Tumor 
incidences were charted from weekly observation. Surviving animals were sacrificed at 52 weeks 
and histopathological evaluations were done on all gross lesions. A highly significant (p<0.01) 
dose-response relationship existed for time to first tumor and for the total number of tumors in 
treated animals. The effect was more pronounced with i.p. and gavage treatment than with topical 
application. However, without application of TPA promotion, no increase occurred in tumor yield, 
either with acrylamide or ethyl carbamate treatment. In this assay system, acrylamide was therefore 
confirmed as being a tumor initiator.
In a bioassay for lung adenoma in mice, groups of 40 male and 40 female, 8-week-old A/J mice 
received doses of 6.25, 12.5, or 25 mg/kg of acrylamide by gavage in an aqueous solution three 
times/week for 8 weeks [Bull et al. 1984a]. Animals were sacrificed at 7 months of age. 
Acrylamide increased the yield of lung adenomas in both sexes in a dose-related manner; the 
average number of tumors per animal increased from 0.2 to 1.4. The dose-response relationship 
was statistically significant (p<0.01) when both the number of animals with tumors and the 
multiplicity of tumors in each dose group were tested using logit regression model analysis. In the 
same investigation, groups of 16 male and 16 female, 8-week-old A/J mice received i.p. injections 
of 1, 3, 10, 30, or 60 mg/kg acrylamide three times/week for 8 weeks. The average number of 
tumors per animal increased from 0.4 to 2.2. The number of lung adenomas increased with the 
dose up to 30 mg/kg. The dose-response relationship was statistically significant (p<0.01) by the 
logit regression model. Because acrylamide increased the lung tumor yield by two routes of 
administration in the absence of a promoter, the authors concluded that acrylamide acted as a 
complete carcinogen in this test system.
In a subsequent study [Bull et al. 1984b], groups of 40 female Swiss-ICR mice were administered 
an oral dose of 0, 12.5, 25, or 50 mg/kg acrylamide six times in a 2-week period. Ethyl carbamate 
served as a positive control and was administered in the same way at concentrations of 50 mg/kg. 
Two weeks after the last dose, a tumor promotion regimen was started. The regimen consisted of 
3 weekly applications of 2.5 fig TPA dissolved in acetone to the shaved back of each animal. 
Another group of mice treated with 50 mg/kg acrylamide did not receive promotion treatment. The 
appearance of skin tumors was observed weekly, and after 52 weeks of study, the surviving animals 
were sacrificed and evaluated histologically for skin and lung tumors. When TPA treatment 
followed, acrylamide produced a dose-related increase in the number of animals that bore skin 
tumors (33% in the high-dose group versus none in the control group). Without TPA treatment 
there was no significant increase. The number of lung tumors (adenoma and carcinoma) was 
increased by acrylamide treatment in a dose-related manner (4 tumors in the control group and 11 
tumors in the 50-mg/kg group). This increase was also observed in the absence of TPA (14 tumors
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in the 50 mg/kg group). This study confirms the initiating effects of acrylamide on the skin of 
Senear mice and the carcinogenic effects of acrylamide on the lungs of A/J mice.
Acrylamide administered in drinking water to female and male F344 rats for 2 years caused a 
statistically significant increase in the incidence of benign and malignant tumors at several sites in 
both sexes [Johnson et al. 1986]. Groups of 90 male and 90 female rats were maintained on drinking 
water providing acrylamide intakes of 0, 0.01, 0.1, 0.5, or 2.0 mg/kg per day. Ten rats per sex per 
treatment group were randomly selected for examination after 6, 12, or 18 months of study. 
Cumulative mortality showed no apparent dose relationship until the 21st month of study. From 
that time to the conclusion of the study at 24 months, mortality increased in the group receiving
2.0 mg/kg per day. No overt signs of neurotoxicity or other effects were attributable to acrylamide 
treatment. Rats in the group receiving the highest dose had an increased number of palpable 
masses, subsequently identified as subcutaneous or skin tumors. The number of tumors by site is 
listed in Table 5. In females, tumor incidence increased in the mammary glands, CNS, thyroid gland 
follicular epithelium, oral tissues, uterus, and clitoral gland. In males, tumor incidence increased 
in the CNS, the thyroid gland follicular epithelium, and the scrotal mesothelium. These increases 
occurred in the group receiving the highest dose (2.0 mg/kg per day). The only statistically 
significant increases (p<0.05) at the 0.5-mg/kg per day dose were the incidence of scrotal 
mesotheliomas in male rats and the incidence of combined mammary and clitoral gland tumors in 
female rats [Johnson et al. 1986].
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Table 5. Pooled tumor incidence data in F344 rats*
Dose of acrylamide (m g/kg per day)
Rat 0.0 0.01 0.1 0.5 2.0
Males:
Number of animals 
with tumors+ 
(testes, thyroid, 
adrenal*) 7 /57 8/53 13/57 14/53 22/54
Number of animals 
with malignant 
tumors (testes) 3 /57 0/53 7/57 11/53 10/54
Females:
Number of animals 
with tumors+ 
(thyroid, mammary, 
CNS", oral, uterus) 13/60 18/60 14/60 21/60 46/60
Number of animals 
with malignant 
tumors (thyroid, 
mammary, CNS, 
uterus) 4 /60 5/60 3/60 4/60 20/60
Adapted from Johnson et al. [1986] study of rats exposed to acrylamide in drinking water for 
24 months.
+ Benign or malignant. Site must be statistically significant at the high dose (treated versus control) for 
tumors to be considered.
1 Includes only adrenal benign tumors.
Tumors only (no "proliferations").
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3 METHODS FOR MONITORING EXPOSURES
3.1 EXPOSURE MONITORING
A worker’s exposure to airborne acrylamide should be determined by using a personal sampling 
train consisting of a glass-fiber filter in a Swinnex cassette (13-mm) followed by a silica gel tube. 
Plastic cassettes (37-mm) yielded poor recoveries of acrylamide and are therefore unsuitable. 
Samples should be collected at a maximum flowrate of 1 liter/min for a minimum of 2 hr; the 
maximum air volume should be 120 liters. The silica gel tube should then be treated with methanol 
to extract the acrylamide. An important step in this method is the transfer of the glass-fiber filters 
to glass vials containing 1 ml of methanol immediately after sampling to avoid losses of acrylamide 
from the filter by evaporation. Analysis should be conducted by gas chromatography using a 
nitrogen/phosphorus detector. The limit of detection for this procedure is 1.3 parts per billion 
(ppb) (0.004 mg/m3). This method is described in Method 21 of the OSHA Analytical Methods 
Manual [OSHA 1985].
3.2 BIOLOGICAL MONITORING
The International Programme on Chemical Safety (IPCS) has recommended that a biological 
monitoring method for acrylamide be developed based on the determination of the adduct formed 
with hemoglobin [WHO 1985]. However, no biological monitoring test acceptable for routine use 
has yet been developed for acrylamide.
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4 RELATIONSHIP BETWEEN EXPOSURE AND 
ADVERSE HEALTH EFFECTS
No data are available from studies in humans to establish an occupational exposure limit for 
acrylamide on the basis of neurotoxic, developmental, reproductive, or carcinogenic effects. 
However, many studies demonstrate a relationship between exposure and adverse health effects in 
animals. These studies are the bases for occupational exposure limits recommended by many 
organizations and government agencies. A few of these studies are described here.
EPA has used results from studies in animals to determine no-observable-effect levels (NOELs) and 
lowest-observable-effect levels (LOELs). With the use of the appropriate uncertainty factors, EPA 
has also recommended a "safe" concentration for human exposure (i.e., a concentration that is not 
expected to produce adverse health effects in exposed individuals) [EPA 1988b].
In 1988, EPA performed a detailed risk assessment of acrylamide based on animal studies of 
neurotoxicity, carcinogenicity, and reproductive effects [EPA 1988a]. Studies of neurotoxic effects 
in animals are summarized in Table 6. The NOEL was 0.2 to 2.0 mg/kg per day and the LOEL 
was 1.0 to 3.0 mg/kg per day. The reference dose (RfD) for acrylamide exposure (formerly 
acceptable daily intake, ADI) was calculated as 0.0002 mg/kg per day [EPA 1988b]. This value is 
based on an NOEL for neurotoxicity in a subchronic rat study of 0.2 mg/kg per day [Burek et al. 
1980]. The exposure to 0.0002 mg/kg per day corresponds with a TWA concentration of 
0.0014 mg/m3 (assuming an average 70-kg human breathing 10 m3 of air in an average working day 
with 100% absorption), which is approximately 20-fold lower than the OSHA PEL of 0.03 mg/m3. 
The RfD was obtained by dividing the NOEL by a factor of 1,000 to account for the use of animal 
data and subchronic exposure. This safety (uncertainty) factor was suggested by the National 
Academy of Science [NAS 1977].
A designation of B2 (probable human carcinogen) was proposed according to EPA cancer guidelines 
on the basis of data from studies of two different animal species [EPA 1988a]. Because risks at low 
exposures cannot be measured directly by experiments in animals or by epidemiologic studies, a 
number of mathematical models have been developed to extrapolate from high to low doses. To 
assess the cancer risk posed by acrylamide, EPA used a linear model (i.e., linearized multistage 
procedure) [EPA 1988a]. Data from the Johnson et al. [1986] study were used to estimate risk from 
acrylamide exposure. The EPA guidelines for cancer risk assessment recommend pooling tumor 
incidence data on the grounds that risk estimates derived from the incidence of site-specific tumors 
may not predict (and may in fact underestimate) whole-body risks that are determined with the 
pooled animal data. The dose-response curves for each sex are based on the pooled tumor 
incidence (benign and malignant) and comprise the data sets of choice for risk assessment. The 
most sensitive sex and species observed in this study (female rats) was chosen to represent possible 
human risk.
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Table 6. Key animal studies of the neurotoxic effects of subchronic and 
chronic exposure to acrylamide*’*
Reference
Species
(route)
Exposure
duration
NOEL*
(m g/kg)
LOEL*
(mg/kg)
Burek et al. 1980 Rats 90 days 0.2 1.0
Johnson et al. 1986 Rats 2 j ars 0.5 2.0
Hamblin 1956 Cats (i.v.) 180 days 1.0
Kuperman 1958 Cats (i.p.) 125 days 1.0
McCollister et al. 1964 Cats 1 year 0 3 1.0
McCollister et al. 1964 Monkeys 1 year 1.0 3.0
Spencer 1979 Monkeys 1 year 2.0 3.0
Schaumburg et al. 1982 Monkeys 1.5 years 1.0
Adapted from EPA [1988a].
+ All studies here except the two noted used the oral route of administration.
5 NOEL = no-observable-effect level; LOEL = lowest-observable-effect level.
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4 Relationship Between Exposure and Adverse Health Effects
The linearized multistage procedure was followed by EPA [1988a], with GLOBAL 86 as the 
computer program. Among the models that showed adequate fit with one to six stages, the model 
that gave the least q^ (slope factor) was selected as the model with which to calculate carcinogenic 
risks using the lifetime average daily exposures provided by the exposure assessment for acrylamide. 
For the female rats with tumors of the thyroid, oral cavity, uterus, CNS, or mammary glands, this 
model had two stages. The cancer potency factor obtained for acrylamide by the linearized 
multistage procedure was 4.5 (mg/kg per day)'1. The cancer potency factor describes the increased 
risk of developing cancer over a 70-year lifetime per unit of exposure where the unit of exposure 
is expressed as mg chemical/kg body weight per day. When based on an experimental animal study, 
the cancer potency factor is the 95% upper confidence limit slope of the dose-response relationship 
for a carcinogen as the dose approaches zero. Calculated upper-bound excess risks for individuals 
exposed to acrylamide are presented in Table 7. The highest risks were estimated for sewer repair 
workers, whose excess risks ranged from 10'1 to 10'2. EPA calculated that exposure to airborne 
concentrations of 0.03 mg/m3 for a working lifetime of 40 years would result in an excess cancer risk 
of 2xl0'3 [EPA 1988a].
The previous American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit 
value (TLV®) of 0.3 mg/m3 [ACGIH 1971] was derived from a study of a small number of cats 
orally dosed with acrylamide and observed for neurotoxic effects [McCollister et al. 1964]. No 
effects were observed after feeding the cats acrylamide at the rate of 0.3 and 1 mg/kg per day, 
5 days/week for 1 year. On the basis of these data, ACGIH recommended that human exposures 
not exceed a total intake of 0.05 mg/kg per day. The average 70-kg human who breathes 10 m3 
of air in an average working day would not exceed this recommended exposure limit if he or she 
were exposed solely to airborne concentrations that did not exceed 0.3 mg/m3—the TLV adopted 
by ACGIH.
In 1989, OSHA adopted a new PEL for acrylamide—0.03 mg/m3 with a skin notation [29 CFR 
1910.1000]. This new PEL was based on the increased incidence of cancer in laboratory animals 
and demonstrated dermal absorption of acrylamide [54 Fed. Reg. 2332]. NIOSH agreed with the 
proposed PEL of 0.03 mg/m3 and the supporting evidence of carcinogenicity [NIOSH 1988].
The World Health Organization reviewed cases of acrylamide poisoning in humans [WHO 1985]. 
Acute exposure to high doses of acrylamide appeared to affect the CNS, and long-term cumulative 
exposure to smaller doses produced peripheral neuropathy. Signs of peripheral neuropathy 
appeared after a latent period, which was dose-dependent and decreased with increasing dose.
On the basis of these neurotoxicity data, the World Health Organization recommended that the 
exposure not exceed a daily intake of 0.012 mg/kg body weight [WHO 1985]. For the average 70-kg 
human who breathes 10 m3 of air in an average working day, is occupationally exposed to airborne 
concentrations only, and has 100% absorption, this intake would result from breathing air with an 
acrylamide concentration of 0.094 mg/m3. This recommendation did not consider the risk of cancer 
or interference with reproduction.
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Table 7. Estimates of excess cancer risk for individuals 
exposed to acrylamide over a lifetime*
Exposure category
Upper-bound 
individual risk estimates
Manufacturing/processing 10'3 -  10'2
Soil grouting (sewer workers) 10'2 -  Iff1
Drinking water 10* -  10 s+
Adapted from EPA [1988a].
+ Worst case to typical case, based on residual acrylamide allowed.
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5 RESEARCH NEEDS
Very few studies address dermal absorption of acrylamide, although the dermal route may be the 
most significant one for acrylamide exposure in the workplace [He et al. 1989]. Therefore, 
quantitative studies should be performed to assess the absorption of aciylamide through the skin. 
Because dermal exposure appears to be a significant route of acrylamide uptake and it is difficult 
to monitor dermal exposures routinely, it is important to develop biomonitoring that can accurately 
reflect total exposure to acrylamide. A valid biomonitoring technique for acrylamide is presently 
unavailable. However, the literature on the toxicokinetics of acrylamide indicates that biomoni­
toring may be feasible either in urine or blood. More than 50% of the given dose is reported to 
be excreted in urine as the metabolite N-acetyl-S-(3-amino-3-oxy-propyl)cysteine [Miller et al. 1982]. 
By collecting the urine of workers whose exposure is monitored, it may be feasible to correlate the 
total exposure (that is, both inhalation and skin) to acrylamide with measured concentrations or 
total amounts of metabolites in 24-hr urine samples.
Another possibility for biomonitoring is measurement of acrylamide binding to red blood cells. 
Hashimoto and Aldridge [1970] observed that after rats received a single i.v. dose of UC acrylamide, 
the radioactivity in blood after 24 hr was entirely associated with red blood cells. Miller et al. [1982] 
found that the concentration of 14C in whole blood reached a plateau at 12% of the total dose after 
1 hr and remained constant throughout the time period examined (7 days). The binding to 
erythrocytes accounted for essentially all of the remaining radioactivity in the whole blood. In vitro 
studies showed that acrylamide was covalently bound to cysteine residues in protein and, on acidic 
hydrolysis, the adduct yielded a compound with chromatographic properties identified as 
S-(2-carboxyethyl)cysteine (CEC) [Hashimoto and Aldridge 1970; Bailey et al. 1986].
Bailey et al. [1986, 1987] used gas chromatography to measure the presence of CEC in red blood 
cells of rats dosed with less than 1 mg/kg. Research is needed to increase the sensitivity of the 
method (using high-performance liquid chromatography and ion chromotography) and to determine 
its applicability to human biomonitoring.
Another area that may require more research is elucidation of dose-response relationships for 
neurotoxic effects. The quantitative data on dose response were adequately addressed in only one 
species (rat) [Burek et al. 1980]. Better quantitative studies in other species (mice, cats, or rabbits) 
may be useful.
In light of the reported genotoxicity and carcinogenicity of acrylamide, information on the binding 
of this compound to DNA is of considerable interest [Moore et al. 1987, Bull et al. 1984a, 1984b; 
Johnson et al. 1986]. Studies addressing the mechanisms of genotoxicity (in vivo and in vitro DNA 
binding and effects) would be useful.
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Acrylamide is widely used in research laboratories for making polyacrylamide gels. EPA estimated 
that 100,000 to 200,000 U.S. laboratory workers are potentially exposed [EPA 1988a]. Because 
exposure data are currently not available on this working population, a survey of potential exposure 
to acrylamide in research laboratories would be very useful.
6 DISCUSSION AND EVALUATION
Studies in rats and mice indicate an association between the induction of cancer and exposure to 
acrylamide. Four types of response have been generally accepted as evidence of induction of 
neoplasms (tumors) [Williams and Weisburger 1986]: (1) the presence of tumors not observed in 
controls, (2) an increase in the incidence of a specific tumor type observed in controls, (3) the 
development of tumors earlier than those observed in controls, and (4) an increased number of 
tumors per animal. Acrylamide satisfies all these criteria. An increased incidence of tumors was 
observed in one strain of rats (female and male F344) and three strains of mice (male and female 
A/J, and female Senear and Swiss-ICR). Increased incidences of lung adenoma and carcinoma 
occurred in ICR-Swiss female mice dosed by gavage six times over a period of 2 weeks. Similar 
increases in lung tumor incidence were observed in A /J male and female mice. In female and male 
rats, the increases in tumor incidence occurred at multiple sites (testes, thyroid, and adrenal gland 
in males and mammary gland, CNS, oral tissues, uterus, and ciitoral gland in females). The 
incidence of tumors was dose-related both in rats and mice. In A /J mice, acrylamide increased the 
yield of lung tumors in both sexes in a dose-related manner. In addition, a highly significant dose- 
response relationship existed for the time to occurrence of first tumors and for the number of 
tumors per animal in female Senear mice.
Although carcinogenicity has not been demonstrated in workers occupationally exposed to 
acrylamide, the limitations of the epidemiologic studies preclude any conclusions regarding the 
association of exposure to acrylamide monomer and the risk of cancer. Prudent public health 
practice calls for regarding acrylamide as a potential occupational carcinogen.
On the basis of studies in animals, the International Agency for Research on Cancer (IARC) 
determined in 1986 that sufficient evidence existed to conclude that acrylamide was carcinogenic 
in animals and classified it as a 2B carcinogen (a possible human carcinogen) [IARC 1986]. Animal 
studies also indicate that reproduction is adversely affected by acrylamide exposure. Testosterone 
levels were depressed in rats [Ali et al. 1983], and decreased fertility was observed in male mice 
following oral exposure to acrylamide in drinking water [Sakamoto and Hashimoto 1986]. 
Degeneration of testicular epithelial tissue in male mice treated by gavage has been observed 
[Hashimoto 1981], as have dominant lethal effects in male rats exposed by drinking water [Smith 
et al. 1986] and mice exposed i.p. [Shelby et al. 1986]. Oral exposure of male or female mice and 
rats to acrylamide in drinking water has caused an increased resorption rate [Nalco Chemical 
Company 1987; Sakamoto and Hashimoto 1986].
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7 SUMMARY
Acrylamide is an odorless, white, crystalline solid used as a monomer or as a raw material in the 
production of polyacrylamides. Workers potentially exposed to acrylamide monomer are employed 
in acrylamide manufacturing and processing, grouting operations, and research and analytical 
laboratories.
Only the acrylamide monomer is toxic; polyacrylamide products are generally nontoxic. Acrylamide 
monomer may be neurotoxic, carcinogenic, genotoxic, and hazardous to reproduction. Recent 
studies confirm that acrylamide exposures cause cancer and reproductive effects in animals, but 
epidemiologic studies have not demonstrated these effects in humans.
Key Words: Acrylamide, carcinogenicity, dermal exposures, grouting, neurotoxic effects,
occupational exposure, polyacrylamide, reproductive effects.
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9 APPENDIX. INTERNATIONAL STANDARDS FOR 
WORKPLACE EXPOSURES TO ACRYLAMIDE
This appendix lists occupational exposure limits for airborne acrylamide in various countries (Table 
A -l), and it contains a discussion of the bases for other recommendations that depart from the 
frequently cited limit of 0.3 mg/m3.
Table A-l. Occupational exposure limits* for airborne acrylamide 
in various countries*
(mg/m3)
Country
Time-weighted average 
(TWA)
Short-term 
exposure limit 
(STEL) Ceiling
Austria 0.3
Belgium S+ 0.3 — —
Denmark s 0.3 — —
Federal Republic 
of Germany s 0.3 -
Finland 0.3 0.9 —
Hungary s 0.3 S 1.5 —
Indonesia s 0.3 --- —
Italy s 0.3 - —
Japan 0.3 - —
Korea 0.3 0.6 —
Mexico s 0.3 — —
Netherlands s 0.3 — —
Sweden s 0 3 S 0.9 —
Switzerland s 0.3 — —
Taiwan 0.3 — —
United Kingdom s 0.3 S 0.6 —
United States (OSHA) s 0.03* — —
Venezuela s 0.3 — S 0.6
Yugoslavia s 0.3 — —
Adapted from Cook [1987].
+ "S" denotes potential absorption into the body through the skin.
* In 1989, the Occupational Safety and Health Administration (OSHA) changed its permissible exposure 
limit (PEL) from S 0.3 m g/m 3 to S 0.03 m g/m 3 (TWA) [29 CFR 1910.1000].
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In 1976, the National Institute for Occupational Safety and Health (NIOSH) recommended an 
exposure limit (REL) for acrylamide of 0.3 mg/m3 (0.1 ppm) as a time-weighted average (TWA) 
for up to a 10-hr workshift (40 hr per week) [NIOSH 1976]. At that time, the available human and 
animal studies did not provide enough information to alter the previously established OSHA 
permissible exposure limit (PEL) of 0.3 mg/m3 as an 8-hr TWA. The original OSHA PEL was 
based on the 1968 American Conference of Governmental Industrial Hygienists (ACGIH) threshold 
limit value (TLV®) [ACGIH 1971], which was derived mainly from a study of a small number of 
cats orally dosed with acrylamide and observed for neurotoxic effects [McCollister et al. 1964]. No 
effects were observed after feeding the cats acrylamide at the rate of 0.3 and 1 mg/kg per day, 
5 days/week for 1 year.
The current Swedish standard for acrylamide [TWA = 0.3 mg/m3] is the same as the previous 
ACGIH recommendation, with an added short-term exposure limit (STEL) of 0.9 mg/m3.
Since 1968, ACGIH has designated acrylamide as an A2 substance (suspected human carcinogen) 
and assigned it a TLV of 0.03 mg/m3 (0.01 ppm) as an 8-hr TWA with a skin notation [ACGIH
1986]. The revised TLV was based on data indicating a carcinogenic response in rats exposed to 
acrylamide in drinking water [Johnson et al. 1986]. The skin notation was assigned because of the 
demonstrated dermal absorption of acrylamide.
On the basis of studies in animals, the International Agency for Research on Cancer (IARC) 
determined in 1986 that there was sufficient evidence to conclude that acrylamide was carcinogenic 
in animals [IARC 1986] and classified it as a 2B carcinogen (a possible human carcinogen) [IARC
1987],
The World Health Organization recommended that acrylamide exposure not exceed a daily intake 
of 0.012 mg/kg body weight [WHO 1985]. For the 70-kg human who breathes 10 m3 of air in an 
average workday, is occupationally exposed to airborne concentrations only, and has 100% 
absorption, this intake would result from breathing air with an acrylamide concentration of
0.094 mg/m3. It should be emphasized that this value is based solely on the neurotoxicity of 
acrylamide and does not take into account the risk of cancer or interference with reproduction.
In 1989, OSHA adopted a new PEL for acrylamide—0.03 mg/m3 as an 8-hr TWA with a skin 
notation [29 CFR 1910.1000]. This new PEL was based on the increased incidence of cancer in 
laboratory animals and demonstrated dermal absorption of acrylamide [54 Fed. Reg. 2332 (1989)]. 
OSHA considered evidence of carcinogenicity derived from the studies by Johnson et al. [1986] and 
Bull et al. [1984a, 1984b] and stated that the evidence was sufficient to conclude that acrylamide is 
a carcinogen. In addition, OSHA cited the ACGIH and IARC evaluations of acrylamide as a 
carcinogen. NIOSH agreed with the proposed PEL of 0.03 mg/m3 and the supporting evidence of 
carcinogenicity [NIOSH 1988].
In 1988, the U. S. Environmental Protection Agency (EPA) proposed a reference dose (RfD) for 
acrylamide exposure (formerly acceptable daily intake, ADI) of 0.0002 mg/kg per day [EPA 1988b]. 
TTie RfD is based on a no-observable-effect level (NOEL) in a subchronic rat study of 0.2 mg/kg 
per day [Burek et al. 1980]. The RfD was obtained by dividing the NOEL by a factor of 1,000 to 
account for the use of animal data and subchronic exposure. This safety (uncertainty) factor was 
suggested by the National Academy of Science [NAS 1977]. The designation of B2 (probable
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human carcinogen) was proposed for acrylamide according to EPA cancer guidelines on the basis 
of data from studies of two different animal species [EPA 1988a].
The U.S. Food and Drug Administration has recommended that residual acrylamide monomer not 
exceed 0.05% in molasses and in beet and cane sugar [37 Fed. Reg. 329 (1972)].
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